目的：分析替罗非班在ST段抬高型急性冠脉综合征介入治疗围手术期中的应用价值。方法：选择接受介入治疗的ST段抬高型急性冠脉综合征患者，并随机将其分为接受常规治疗的对照组和接受替罗非班治疗的观察组，并检测治疗前后患者的血小板CD40L表达、血清CRP水平以及心血管事件发生等情况。结果：①治疗后，观察组患者的血小板CD40L表达强度明显低于对照组患者，差异有统计学意义(t=3.281，P＜0.05)；②给药后1 d、1周和4周观察组患者的血清CRP水平均明显低于对照组患者，差异有统计学意义(t=2.183，t=2.748，t=4.719；P＜0.05)；③接受药物治疗后，观察组患者介入治疗后心血管事件发生率明显低于对照组，差异有统计学意义(x2=6.493，P＜0.05)。结论：围术期替罗非班治疗可以有效降低患者的血小板表达及炎症水平，减少不良心血管事件的发生，具有积极的临床意义。%Objective: To analyze the effect of tirofiban on patients with ST-segment elevation acute coronary syndrome undergoing intervention treatment. Methods: Chosen patients with ST-segment elevation acute coronary syndrome between November 2012 to November 2013 as research subjects,randomly assigned to observed group received conventional treatment and control group received tirofiban perioperative, detecting before and after platelet CD40L expression, serum CRP levels, cardiovascular events. Results:1)After treatment, observed group patients platelet CD40L expression intensity was significantly lower than control group(t=3.281, P<0.05);2) at various time points after dosing, serum CRP in observation group were significantly lower than control group patients (t=2.183, t=2.748, t=4.719;P<0.05);3)After treatment, observation group patients cardiovascular event rate was significantly lower than control group(x2=6.493, P<0.05). Conclusion:Perioperative tirofiban therapy can effectively reduce the expression and inflammation in patients with platelet levels, reduce the incidence of adverse cardiovascular events, with positive clinical significance.
展开▼
